New therapeutic approaches to Alzheimer's disease

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 14, 1996, Pages 30-36

  Schneider, Lon S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; ACETYLCHOLINESTERASE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIOXIDANT; ASCORBIC ACID; CEVIMELINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DESIPRAMINE; DONEPEZIL; GALANTAMINE; INDOMETACIN; METRIFONATE; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC AGENT; NICOTINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PREDNISONE; RIVASTIGMINE; SABCOMELINE; SELEGILINE; TACRINE; UNCLASSIFIED DRUG; XANOMELINE; YOHIMBINE;

ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER TOXICITY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ALZHEIMER DISEASE; ANTIOXIDANTS; CARBAMATES; CHOLINERGIC AGENTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; HUMANS; INDANS; PHENYLCARBAMATES; PIPERIDINES; TACRINE; TRICHLORFON;

EID: 0030464126     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Murphy GM, Tamminga CA. Cortex, XI: amyloid plaques. Am J Psychiatry 1995;152:1258
2. Trojanowski JQ, Lee VM-Y. Phosphorylation of neuronal cytoskeletal proteins in Alzheimer's disease and Lewy body dementias. Ann N Y Acad Sci 1994;747:92-109
3. Bowen DM. Alzheimer's disease. In: Davison AN, Thompson RHS, eds. The Molecular Basis of Neuropathology. London, England: Edward Arnold; 1981:649-665
4. Perry EK, Gibson PH, Blessed G, et al. Neurotransmitter enzyme abnormalities in senile dementia: choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 1977;34: 247-265
5. Bartus RT, Dean RL III, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-417
6. Schneider LS, Tariot PN. Emerging drugs for Alzheimer's disease: mechanisms of action and prospects for cognitive enhancing medications. Med Clin North Am 1994;78:911-934
7. Schneider LS. Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurology 1993;43(suppl 4):S64-S79
8. Stern Y, Sano M, Mayeux R. Long-term administration of oral physostigmine in Alzheimer's disease. Neurology 1988;38:1837-1841
9. Rogers SL, Doody R, Mohs R, et al. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial [abstract]. Neurology 1996;46:A217
10. Rogers SL, Friedhoff LT, Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7:293-303
11. Rogers S. Clinical profile of donepezil (E2020) [abstract). Neurobiol Aging 1996;17:S46
12. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Excelon™ (ENA-713) in Alzheimer's disease: an overview. Journal of Drug Development and Clinical Practice 1996;8:109-116
13. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Development Research 1990;19:425-434
14. Dal-Bianco P, Maly J, Wöber C, et al. Galanthamine treatment in Alzheimer's disease. J Neural Transm 1991;33(suppl):59-63
15. Rogers SL, Yamanishi Y, Yamatsu K. E2020-the pharmacology of a piperidine cholinesterase inhibitor. In: Becker R, Giacobini E, eds. Cholinergic Basis for Alzheimer Therapy. Boston, Mass: Birkhäuser; 1991: 314-320
16. Nordberg A, Lilja A, Lundqvist H, et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging 1992;13:747-758
17. Giacobini E. Cholinomimetic therapy of Alzheimer disease: does it slow down deterioration? In: Racagni G, Brunello N, Langer SZ, eds. Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction, vol 7. Basel, Switzerland: Karger; 1994:51-57
18. Nitsch RM, Slack BE, Wurtman RJ, et al. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992;258:304-307
19. Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin I regulate processing and secretion of the Alzheimer aβ/A4 amyloid protein precursor. Proc Natl Acad Sci U S A 1992;89:10075-10078
20. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991
21. Yamanishi Y, Ogura H, KosasaT, et al. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: comparison with other inhibitors. In: Nagatsu T, Fisher A, Yoshida M, eds. Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, vol 2. New York; NY: Plenum Press; 1990:409-413
22. Giacobini E, Becker R. New cholinesterase inhibitors for treatment of Alzheimer's disease. In: Iqbal K, McLachlan DRC, Winblad B. et al, eds. Alzheimer's Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies. New York, NY: John Wiley & Sons; 1991:627-631
23. Nordgren I, Bergström M, Holmstedt B. et al. Transformation and action of metrifonate. ArchToxicol 1978;41:31-41
24. Hallak M, Giacobini E. A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharmacology 1987;26:521-530
25. Volicer L, Crino PB. Involvement of free radicals in dementia of the Alzheimer type: a hypothesis. Neurobiol Aging 1990;11:567-571
26. LeBel CP, Bondy SC. Oxygen radicals: common mediators of neurotoxicity. Neurotoxicol Teratol 1991;13:341-346
27. Tariot PN, Schneider LS, Patel SV, et al. Alzheimer's disease and l-deprenyl: rationales and findings. In: Szelenyi I, ed. Inhibitors of Monoamine Oxidase B: Pharmacology and Clinical Use in Neurodegenerative Disorders. Basel, Switzerland: Birkhäuser Verlag; 1993:301-317
28. Smith CD, Camey JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A 1991;88:10540-10543
29. Bowen DM, Davison AN. Can the pathophysiology of dementia lead to rational therapy? In: Crook T, Bartus RT, Ferns S, et al, eds. Treatment Development Strategies for Alzheimer's Disease. Madison, Conn: Mark Powley Associates; 1986:35-66
30. Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989;26:689-690
31. Sano M, Growdon J, Klauber M, et al. Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicenter clinical trial of selegiline and αtocopherol [abstract]. Neurology 1995;45(suppl 4):A289
32. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996;47:166-177
33. Minthon L, Gustafson L, Dalfelt G, et al. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 1993;4:32-42
34. Nordberg A, Viitanen M, Winblad B. Nya studier kring Alzheimers sjukdom: lovande behandlingsresultat med takrin. Läkartidningen 1993; 90:1561-1563
35. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994;151:1105-1113
36. McGeer PL, McGeer EG, Rogers J, et al. Does anti-inflammatory treatment protect against Alzheimer's disease? In: Khachaturian ZS, Blass JP, eds. Alzheimer's Disease: New Treatment Strategies. New York, NY: Marcel Dekker; 1992:165-171
37. McGeer PL, McGeer E, Rogers J, et al. Anti-inflammatory drugs and Alzheimer disease [letter]. Lancet 1990;335:1037
38. Breitner JCS, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994;44:227-232
39. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomelhacin in Alzheimer's disease. Neurology 1993;43:1609-1611
40. Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 1993;33:536-541
41. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6
42. Schneider LS, Farlow MR. Predicting response to cholinesterase inhibitors in Alzheimer's disease: possible approaches. CNS Drugs 1995;4:114-124
43. Schneider LS, Farlow MR, Henderson VW, et al. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46:1580-1584
44. Perryman KM, Fitten LJ. Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease. Life Sci 1993;53:479-486
45. Farlow MR, Brashear A, Hui S, et al. The effects of tacrine in patients with mild versus moderate stage Alzheimer's disease. In: Iqbal K, Mortimer JA, Winblad B, et al, eds. Research Advances in Alzheimer's Disease and Related Disorders. New York, NY: John Wiley & Sons; 1995:283-292
46. Levy R, Eagger S, Griffiths M, et al. Lewy bodies and response to tacrine in Alzheimer's disease [letter]. Lancet 1994;343:176
47. Wilcock GK, Scott M, Pearsall T. Long-term use of tacrine [letter]. Lancet 1994;343:294
48. Gottfries CG. Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology (Berl) 1985;86: 245-252
49. Sunderland T, Molchan S, Lawlor B, et al. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl. Int Psychogeriatr 1992;4(suppl 2):291-309
50. Haroutunian V, Kanof PD, Tsuboyama G, et al. Restoration of cholinomimetic activity by clonidine in cholinergic plus noradrenergic lesioned rats. Brain Res 1990;507:261-266
51. Mittelman MS, Ferris SH, Steinberg G, et al. An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spousecaregivers. Gerontologist 1993;33:730-740